Abstract
Background: FcγRIIb is the only inhibitory IgG receptor, which is divided into three subtypes of FcγRIIb1, FcγRIIb2 and FcγRIIb3. It is mainly responsible for the immune balance in vivo by cross-linking with the activated receptor to intracellular transduction inhibitory signals, and it plays an important biological role in the negative regulation of innate immunity and adaptive immunity. An abnormal expression of FcγRIIb on cells would result in autoimmune diseases, infectious diseases, and so forth.
Conclusion: FcγRIIb modulates immune responses and further treats related diseases by inhibiting the activation of B lymphocytes, monocytes, mast cells, and basophils induced by activating receptors. It can be used in biotherapeutic methods such as monoclonal antibodies, chimeric recombinant proteins, bispecific antibodies, etc. Our increased understanding of FcγRIIb function also has a foundation for further research and development of FcγRIIb, which also provides potentially farreaching therapeutic implications.
Keywords: FcγRIIb, IgG receptor, BCR, Fc receptor, biological function, ITIM.
Protein & Peptide Letters
Title:The Unique Inhibitory IgG Receptor--FcγRIIb
Volume: 25 Issue: 11
Author(s): Zhenzhen Xu, Lipeng Liu, Zhe Cui, Kewei Bi, Nan Zhang, Yanfen Zhang*Zhongcheng Liu*
Affiliation:
- Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Baoding 071002,China
- Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Baoding 071002,China
Keywords: FcγRIIb, IgG receptor, BCR, Fc receptor, biological function, ITIM.
Abstract: Background: FcγRIIb is the only inhibitory IgG receptor, which is divided into three subtypes of FcγRIIb1, FcγRIIb2 and FcγRIIb3. It is mainly responsible for the immune balance in vivo by cross-linking with the activated receptor to intracellular transduction inhibitory signals, and it plays an important biological role in the negative regulation of innate immunity and adaptive immunity. An abnormal expression of FcγRIIb on cells would result in autoimmune diseases, infectious diseases, and so forth.
Conclusion: FcγRIIb modulates immune responses and further treats related diseases by inhibiting the activation of B lymphocytes, monocytes, mast cells, and basophils induced by activating receptors. It can be used in biotherapeutic methods such as monoclonal antibodies, chimeric recombinant proteins, bispecific antibodies, etc. Our increased understanding of FcγRIIb function also has a foundation for further research and development of FcγRIIb, which also provides potentially farreaching therapeutic implications.
Export Options
About this article
Cite this article as:
Xu Zhenzhen , Liu Lipeng , Cui Zhe, Bi Kewei, Zhang Nan, Zhang Yanfen*, Liu Zhongcheng*, The Unique Inhibitory IgG Receptor--FcγRIIb, Protein & Peptide Letters 2018; 25 (11) . https://dx.doi.org/10.2174/0929866525666181026162216
DOI https://dx.doi.org/10.2174/0929866525666181026162216 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Advancing the Understanding of Regulatory Mechanisms and Diseases Through Biochemistry and Structural Biology
Modern research is increasingly interested in understanding the regulatory mechanisms and diseases through various integrative approaches. Biochemistry and structural biology offer valuable atomic-level insights that help unravel the complexities of cellular regulatory mechanisms and their association with health and disease. The unique advantage of these fields is that they provide ...read more
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidized Human Beta2-Glycoprotein I: Its Impact on Innate Immune Cells
Current Molecular Medicine The Role of Mitochondria in Systemic Lupus Erythematosus: A Glimpse of Various Pathogenetic Mechanisms
Current Medicinal Chemistry Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Case-control Association Study of Autoimmunity Associated Variants in PDCD1 and Juvenile Idiopathic Arthritis
Current Rheumatology Reviews α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management
Endocrine, Metabolic & Immune Disorders - Drug Targets The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Inhibitory BCR Co-Receptors in Immunity
Infectious Disorders - Drug Targets Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Synthesis and Evaluation of Cytotoxicity and Inhibitory Effect on Nitric Oxide Production by J774A.1 Macrophages of New Anthraquinone Derivatives
Medicinal Chemistry